Capital International Investors Buys 55,511 Shares of CRISPR Therapeutics AG $CRSP

Capital International Investors increased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 1.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,649,258 shares of the company’s stock after buying an additional 55,511 shares during the quarter. Capital International Investors owned approximately 0.06% of CRISPR Therapeutics worth $366,128,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Capital Group Investment Management PTE. LTD. lifted its stake in CRISPR Therapeutics by 6.6% in the third quarter. Capital Group Investment Management PTE. LTD. now owns 12,943 shares of the company’s stock valued at $839,000 after acquiring an additional 798 shares during the last quarter. Swiss National Bank increased its stake in shares of CRISPR Therapeutics by 1.7% during the 3rd quarter. Swiss National Bank now owns 159,100 shares of the company’s stock worth $10,311,000 after purchasing an additional 2,700 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in shares of CRISPR Therapeutics in the 3rd quarter valued at about $2,724,000. Rathbones Group PLC bought a new stake in shares of CRISPR Therapeutics in the 3rd quarter valued at about $201,000. Finally, SR One Capital Management LP lifted its stake in CRISPR Therapeutics by 94.4% in the 3rd quarter. SR One Capital Management LP now owns 2,038,763 shares of the company’s stock valued at $132,132,000 after purchasing an additional 989,812 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Key CRISPR Therapeutics News

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: The debt raise could extend runway for CRISPR’s pipeline and may be value-accretive long-term if it funds high-return programs; some analysts/commentary view the financing as strategically sensible despite short-term pain. This Is Why CRISPR Therapeutics Stock Is Tumbling on Tuesday
• Positive Sentiment: Some hedge-fund/retail write-ups highlight CRISPR as an attractive biotech exposure — increased interest from active investors can support upside if clinical milestones progress. Here is Why CRISPR Therapeutics (CRSP) Appears so Good
• Neutral Sentiment: There is circulating short-interest data flagged as a “large increase,” but the reported figures appear to be erroneous/zero (NaN/0 shares). Short-interest reporting here is unreliable, so don’t treat it as a confirmed driver.
• Neutral Sentiment: Analyst/deal speculation: pieces are discussing potential strategic outcomes (including takeover talk), but these remain speculative and not confirmed catalysts. Is A Vertex Buyout Of Crispr Therapeutics Inevitable? Here’s My Take
• Negative Sentiment: CRISPR announced a proposed private offering of convertible senior notes due 2031 for $350M (plus an option for $52.5M). Convertibles raise immediate funding but create dilution/conversion risk and can pressure the stock on the announcement. CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering
• Negative Sentiment: Market reaction: multiple outlets report shares dropped after the convertible-notes announcement; trading volume is elevated, indicating aggressive selling/positioning. CRISPR Therapeutics shares drop after announcing convertible notes sale
• Negative Sentiment: Broader fundamentals: recent quarterly results missed revenue and EPS expectations and the company shows deep losses — analysts remain cautious (e.g., Morgan Stanley’s underweight stance), which amplifies negative reaction to dilution/financing news.

Analyst Ratings Changes

A number of equities analysts recently commented on CRSP shares. Citigroup reiterated a “buy” rating on shares of CRISPR Therapeutics in a report on Monday, February 16th. Morgan Stanley reaffirmed an “underweight” rating and issued a $33.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday, February 17th. Citizens Jmp reduced their target price on CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating for the company in a research note on Friday, January 30th. Chardan Capital boosted their target price on CRISPR Therapeutics from $74.00 to $76.00 and gave the stock a “buy” rating in a report on Saturday, February 14th. Finally, TD Cowen increased their price target on CRISPR Therapeutics from $40.00 to $45.00 and gave the company a “hold” rating in a research note on Friday, February 13th. Ten research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $64.24.

Insider Buying and Selling

In related news, CEO Samarth Kulkarni sold 60,000 shares of the business’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $60.23, for a total value of $3,613,800.00. Following the completion of the sale, the chief executive officer directly owned 134,201 shares in the company, valued at $8,082,926.23. The trade was a 30.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, General Counsel James R. Kasinger sold 2,112 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $52.58, for a total value of $111,048.96. Following the completion of the transaction, the general counsel directly owned 85,115 shares in the company, valued at approximately $4,475,346.70. This represents a 2.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 99,079 shares of company stock worth $5,643,674. 4.10% of the stock is owned by corporate insiders.

CRISPR Therapeutics Stock Performance

Shares of CRSP opened at $52.80 on Wednesday. The firm has a market cap of $5.07 billion, a P/E ratio of -8.10 and a beta of 1.72. CRISPR Therapeutics AG has a 52 week low of $30.04 and a 52 week high of $78.48. The firm’s 50-day simple moving average is $54.32 and its 200 day simple moving average is $57.39.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Thursday, February 12th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.15) by ($0.22). CRISPR Therapeutics had a negative return on equity of 26.31% and a negative net margin of 16,569.77%.The company had revenue of $0.86 million for the quarter, compared to analyst estimates of $4.72 million. During the same quarter last year, the business earned ($1.01) earnings per share. The company’s revenue was down 97.8% on a year-over-year basis. As a group, equities analysts forecast that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

CRISPR Therapeutics Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.